BC-819, a plasmid comprising the H19 gene regulatory sequences and diphtheria toxin A, for the potential targeted therapy of cancers - PubMed (original) (raw)
Affiliations
- PMID: 20886393
BC-819, a plasmid comprising the H19 gene regulatory sequences and diphtheria toxin A, for the potential targeted therapy of cancers
Marc C Smaldone et al. Curr Opin Mol Ther. 2010 Oct.
Abstract
BC-819 (DTA-H19), in development by BioCancell Therapeutics Inc, under license from the Hebrew University of Jerusalem, is a double-stranded DNA plasmid carrying the gene for the A subunit of diphtheria toxin under the regulation of the H19 gene promoter. H19, a paternally imprinted, oncofetal gene, encodes an RNA that acts as a riboregulator. Expressed at substantial levels in embryonic and malignant tissues, but minimally or not expressed in adult tissues, elevated H19 RNA expression has been observed in over 30 malignancies prompting investigation into its utility as a targeted therapeutic agent. While most in vivo studies have investigated BC-819 for the treatment of bladder cancer, recent studies have also yielded encouraging results in NSCLC,colon, pancreatic and ovarian cancers. A phase I/IIa clinical trial in patients with non-muscle invasive bladder cancer receiving intravesical BC-819 reported mild local toxicity and complete and partial response rates of 22 and 44%, respectively. At the time of publication, a phase IIb trial was ongoing in patients with bladder cancer, while phase I/II clinical trials in patients with ovarian and pancreatic cancer were accruing participants. This review provides a focused summary of the existing experimental evidence demonstrating the effectiveness of the plasmid construct, early clinical outcomes and a discussion of the potential role of BC-819 as a targeted cancer therapy.
Similar articles
- Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer.
Hanna N, Ohana P, Konikoff FM, Leichtmann G, Hubert A, Appelbaum L, Kopelman Y, Czerniak A, Hochberg A. Hanna N, et al. Cancer Gene Ther. 2012 Jun;19(6):374-81. doi: 10.1038/cgt.2012.10. Epub 2012 Apr 13. Cancer Gene Ther. 2012. PMID: 22498722 Clinical Trial. - Phase I/II marker lesion study of intravesical BC-819 DNA plasmid in H19 over expressing superficial bladder cancer refractory to bacillus Calmette-Guerin.
Sidi AA, Ohana P, Benjamin S, Shalev M, Ransom JH, Lamm D, Hochberg A, Leibovitch I. Sidi AA, et al. J Urol. 2008 Dec;180(6):2379-83. doi: 10.1016/j.juro.2008.08.006. Epub 2008 Oct 31. J Urol. 2008. PMID: 18950807 - SNS-595, a naphthyridine cell cycle inhibitor and stimulator of apoptosis for the treatment of cancers.
Mills DA, Fekrazad HM, Verschraegen CF. Mills DA, et al. Curr Opin Investig Drugs. 2008 Jun;9(6):647-57. Curr Opin Investig Drugs. 2008. PMID: 18516764 Review. - Use of preclinical models to assess the therapeutic potential of new drug candidates for bladder cancer.
Amit D, Gofrit ON, Matouk I, Birman T, Hochberg A. Amit D, et al. Semin Oncol. 2012 Oct;39(5):534-42. doi: 10.1053/j.seminoncol.2012.08.006. Semin Oncol. 2012. PMID: 23040250 Review.
Cited by
- Regulation and Therapeutic Application of Long non-Coding RNA in Tumor Angiogenesis.
Zhang S, Xia Y, Chen W, Dong H, Cui B, Liu C, Liu Z, Wang F, Du J. Zhang S, et al. Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241273239. doi: 10.1177/15330338241273239. Technol Cancer Res Treat. 2024. PMID: 39110070 Free PMC article. Review. - Novel immunotherapeutic options for BCG-unresponsive high-risk non-muscle-invasive bladder cancer.
Hannouneh ZA, Hijazi A, Alsaleem AA, Hami S, Kheyrbek N, Tanous F, Khaddour K, Abbas A, Alshehabi Z. Hannouneh ZA, et al. Cancer Med. 2023 Dec;12(24):21944-21968. doi: 10.1002/cam4.6768. Epub 2023 Dec 1. Cancer Med. 2023. PMID: 38037752 Free PMC article. Review. - Roles of long noncoding RNA in triple-negative breast cancer.
Das PK, Siddika A, Rashel KM, Auwal A, Soha K, Rahman MA, Pillai S, Islam F. Das PK, et al. Cancer Med. 2023 Oct;12(20):20365-20379. doi: 10.1002/cam4.6600. Epub 2023 Oct 5. Cancer Med. 2023. PMID: 37795578 Free PMC article. Review. - Long noncoding RNA (lncRNA) H19: An essential developmental regulator with expanding roles in cancer, stem cell differentiation, and metabolic diseases.
Liao J, Chen B, Zhu Z, Du C, Gao S, Zhao G, Zhao P, Wang Y, Wang A, Schwartz Z, Song L, Hong J, Wagstaff W, Haydon RC, Luu HH, Fan J, Reid RR, He TC, Shi L, Hu N, Huang W. Liao J, et al. Genes Dis. 2023 Mar 24;10(4):1351-1366. doi: 10.1016/j.gendis.2023.02.008. eCollection 2023 Jul. Genes Dis. 2023. PMID: 37397543 Free PMC article. Review. - The Role of EMT-Related lncRNAs in Ovarian Cancer.
Lampropoulou DI, Papadimitriou M, Papadimitriou C, Filippou D, Kourlaba G, Aravantinos G, Gazouli M. Lampropoulou DI, et al. Int J Mol Sci. 2023 Jun 13;24(12):10079. doi: 10.3390/ijms241210079. Int J Mol Sci. 2023. PMID: 37373222 Free PMC article. Review.